PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation

NYSE:MD • US58502B1061

Current stock price

19.49 USD
-0.07 (-0.36%)
At close:
19.49 USD
0 (0%)
After Hours:

This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MD Profitability Analysis

1.1 Basic Checks

  • MD had positive earnings in the past year.
  • MD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
  • In the past 5 years MD always reported a positive cash flow from operatings.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • With an excellent Return On Assets value of 7.36%, MD belongs to the best of the industry, outperforming 87.13% of the companies in the same industry.
  • The Return On Equity of MD (19.10%) is better than 87.13% of its industry peers.
  • MD's Return On Invested Capital of 9.88% is amongst the best of the industry. MD outperforms 80.20% of its industry peers.
  • MD had an Average Return On Invested Capital over the past 3 years of 8.21%. This is in line with the industry average of 8.94%.
  • The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin of MD (8.64%) is better than 91.09% of its industry peers.
  • In the last couple of years the Profit Margin of MD has grown nicely.
  • The Operating Margin of MD (12.07%) is better than 84.16% of its industry peers.
  • In the last couple of years the Operating Margin of MD has grown nicely.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MD Health Analysis

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MD has been reduced compared to 1 year ago.
  • The number of shares outstanding for MD has been reduced compared to 5 years ago.
  • MD has a better debt/assets ratio than last year.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • MD has an Altman-Z score of 2.01. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • MD has a Altman-Z score of 2.01. This is comparable to the rest of the industry: MD outperforms 52.48% of its industry peers.
  • MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 2.36, MD is doing good in the industry, outperforming 76.24% of the companies in the same industry.
  • A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
  • MD has a Debt to Equity ratio of 0.66. This is comparable to the rest of the industry: MD outperforms 55.45% of its industry peers.
  • Although MD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.01
ROIC/WACC1.21
WACC8.15%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • MD has a Current ratio of 1.66. This is in the better half of the industry: MD outperforms 66.34% of its industry peers.
  • A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
  • The Quick ratio of MD (1.66) is better than 68.32% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.24% over the past year.
  • Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
  • Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.92% in the last year.
  • MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.99% yearly.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.99% yearly.
  • MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. MD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.60, the valuation of MD can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.07% of the companies listed in the same industry.
  • MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.71.
  • The Price/Forward Earnings ratio is 8.47, which indicates a very decent valuation of MD.
  • Based on the Price/Forward Earnings ratio, MD is valued cheaper than 93.07% of the companies in the same industry.
  • MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.83, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.6
Fwd PE 8.47
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MD is valued cheaply inside the industry as 88.12% of the companies are valued more expensively.
  • 92.08% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.4
EV/EBITDA 6.31
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.72
PEG (5Y)0.96
EPS Next 2Y8.67%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MD Dividend Analysis

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MD Fundamentals: All Metrics, Ratios and Statistics

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (3/16/2026, 5:14:06 PM)

After market: 19.49 0 (0%)

19.49

-0.07 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners102.64%
Inst Owner Change1.24%
Ins Owners1.94%
Ins Owner Change-0.8%
Market Cap1.62B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (12.52%)
Short Float %3.35%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-1.3%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-1.72%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 9.6
Fwd PE 8.47
P/S 0.85
P/FCF 6.4
P/OCF 5.97
P/B 1.87
P/tB N/A
EV/EBITDA 6.31
EPS(TTM)2.03
EY10.42%
EPS(NY)2.3
Fwd EY11.81%
FCF(TTM)3.04
FCFY15.62%
OCF(TTM)3.27
OCFY16.76%
SpS23.06
BVpS10.43
TBVpS-4.96
PEG (NY)0.72
PEG (5Y)0.96
Graham Number21.83
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.01
F-Score8
WACC8.15%
ROIC/WACC1.21
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.6 and the Price/Book (PB) ratio is 1.87.